Jan. 14 at 11:54 PM
$GALT "MALO" in liver health stands for Major Adverse Liver Outcomes, a critical term in research for serious liver events like decompensated cirrhosis, liver cancer (HCC), liver failure, or liver transplantation, often seen in conditions like metabolic dysfunction-associated steatotic liver disease (MASLD). These outcomes signify severe liver damage, with liver fibrosis being a key predictor, highlighting the importance of managing metabolic factors like diabetes and obesity to prevent progression to these severe stages.
We need to prevent MALOs. The most recent epidemiology in MASH shows an explosion of MASH cirrhosis and MALOs. We can't wait decades for metabolic drugs, that even in combinations, won't do very much. The path is now wide open for GALT.
